Abstract: Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast skeletal muscle sarcomere through one or more of fast skeletal myosin, actin, tropomyosin, troponin C, troponin I, and troponin T, and fragments and isoforms thereof. The tetrahydroisoquinoline derivative compounds can thus be used as an agent for preventing or treating 1) neuromuscular disorders, 2) disorders of voluntary muscle, 3) CNS disorders in which muscle weakness, atrophy, and fatigue are prominent symptoms, 4) muscle symptoms stemming from systemic disorders, and 5) dysfunctions of pelvic floor and urethral/anal sphincter muscle.

Abstract: Provided is a fifth step for obtaining a removal depth of a second electrode mixture layer (first opaque layer) corresponding to an integrated value from the integrated value of the value corresponding to the number of applying pulses integrated thus far, based on a correlation between the value corresponding to the number of applying pulses of pulse laser and the removal depth of the second electrode mixture layer grasped in advance, once it is determined that a white light applying target has changed from the second electrode mixture layer to a solid electrolyte layer (second opaque layer) and acquiring the removal depth as a thickness of the second electrode mixture layer.

Abstract: A gas detection device includes: a gas sensor that detects a gas based on a change in an electric signal due to adsorption of a gas to be measured; a rotary body having the gas sensor mounted therein; and a motor that rotates the rotary body. The gas sensor is disposed at a location apart from a rotation axis of the rotary body. The motor rotates the rotary body at a constant rate.

Abstract: The metal complex comprises a multivalent carboxylic acid compound, at least one metal ion selected from ions of metals belonging to Groups 2 to 13 of the periodic table, an organic ligand capable of multidentate binding to the metal ion, and a C1 or C2 monocarboxylic acid compound. The metal complex has excellent gas adsorption, storage, and separation performance as well as excellent durability. The metal complex is stably present under high temperature and high humidity, and can maintain high adsorption performance.

Abstract: Provided is a fifth step for obtaining a removal depth of a second electrode mixture layer (first opaque layer) corresponding to an integrated value from the integrated value of the value corresponding to the number of applying pulses integrated thus far, based on a correlation between the value corresponding to the number of applying pulses of pulse laser and the removal depth of the second electrode mixture layer grasped in advance, once it is determined that a white light applying target has changed from the second electrode mixture layer to a solid electrolyte layer (second opaque layer) and acquiring the removal depth as a thickness of the second electrode mixture layer.

Abstract: A thin-film semiconductor device includes a substrate, a second protection layer, and an oxide semiconductor layer between the substrate and the second protection layer. The second protection layer has provided therein at least one through-hole in which an extraction electrode is embedded, the extraction electrode being electrically connected with the oxide semiconductor layer. The second protection layer has film density of 2.80 g/cm3 to 3.25 g/cm3.

Abstract: The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. A tetrahydrobenzothiophene compound of the following formula (I) has NPT-IIb inhibitory action and can be used as an agent for treating and/or preventing hyperphosphatemia: wherein, R1 represents —O-lower alkyl, -lower alkylene-phenyl, or the like; R2 and R3 are the same as or different from each other and represent H, lower alkyl, cycloalkyl, aryl, heteroaryl or the like, or, R2 and R3 may be combined with a nitrogen atom to which they bind to form 5- to 7-membered saturated cyclic amino; R4's are the same as or different from each other and represent halogen, lower alkyl; and n represents 0 to 2.

Abstract: A thin-film semiconductor device includes a substrate, a second protection layer, and an oxide semiconductor layer between the substrate and the second protection layer. The second protection layer has provided therein at least one through-hole in which an extraction electrode is embedded, the extraction electrode being electrically connected with the oxide semiconductor layer. The second protection layer has film density of 2.80 g/cm3 to 3.25 g/cm3.

Abstract: [Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the present invention. The aminoalkyl-substituted N-thienylbenzamide derivative of the present invention has an NPT-IIb inhibitory action and can be used as an agent for preventing and/or treating hyperphosphatemia.

Abstract: The metal complex comprises a multivalent carboxylic acid compound, at least one metal ion selected from ions of metals belonging to Groups 2 to 13 of the periodic table, an organic ligand capable of multidentate binding to the metal ion, and a C1 or C2 monocarboxylic acid compound. The metal complex has excellent gas adsorption, storage, and separation performance as well as excellent durability. The metal complex is stably present under high temperature and high humidity, and can maintain high adsorption performance.

Abstract: [Problem] To provide a compound that has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. [Means for Solution] The present inventors conducted their studies on a compound that has an NPT-IIb inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. As a result, they created an aminoalkyl-substituted N-thienylbenzamide derivative which has NPT-IIb inhibitory action, thereby completing the present invention. The aminoalkyl-substituted N-thienylbenzamide derivative of the present invention has an NPT-IIb inhibitory action and can be used as an agent for preventing and/or treating hyperphosphatemia.

Abstract: The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. A tetrahydrobenzothiophene compound of the following formula (I) has NPT-IIb inhibitory action and can be used as an agent for treating and/or preventing hyperphosphatemia: wherein, R1 represents —O-lower alkyl, -lower alkylene-phenyl, or the like; R2 and R3 are the same as or different from each other and represent H, lower alkyl, cycloalkyl, aryl, heteroaryl or the like, or, R2 and R3 may be combined with a nitrogen atom to which they bind to form 5- to 7-membered saturated cyclic amino; R4's are the same as or different from each other and represent halogen, lower alkyl; and n represents 0 to 2.

Abstract: The purpose is to provide a compound which has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating and/or preventing hyperphosphatemia. A tetrahydrobenzothiophene compound of the following formula (I) has NPT-IIb inhibitory action and can be used as an agent for treating and/or preventing hyperphosphatemia: wherein, R1 represents —O-lower alkyl, -lower alkylene-phenyl, or the like; R2 and R3 are the same as or different from each other and represent H, lower alkyl, cycloalkyl, aryl, heteroaryl or the like, or, R2 and R3 may be combined with a nitrogen atom to which they bind to form 5- to 7-membered saturated cyclic amino; R4's are the same as or different from each other and represent halogen, lower alkyl; and n represents 0 to 2.

Abstract: A compound has an intestinal phosphate transporter (NPT-IIb) inhibitory action and is useful as an active ingredient of an agent for treating hyperphosphatemia, preventing hyperphosphatemia, or both. The compound is a tetrahydrobenzothiophene compound. A pharmaceutical composition for treating hyperphosphatemia includes the compound or salt thereof. A method of treating hyperphosphatemia includes administering to a subject an effective amount of the compound or salt thereof.

Abstract: It is a method for manufacturing a plasma display panel having a discharge space, and a protective layer opposed to the discharge space. A gas containing a reducing organic gas is introduced into the discharge space, and the protective layer is exposed to the reducing organic gas. Then, the reducing organic gas is emitted from the discharge space. Then, a discharge gas is enclosed in the discharge space. The protective layer contains at least a first metal oxide and a second metal oxide. Furthermore, the protective layer has at least one peak in an X-ray diffraction analysis. The peak exists between a first peak of the first metal oxide in the X-ray diffraction analysis, and a second peak of the second metal oxide in the X-ray analysis. The first peak and the second peak show the same surface orientation as a surface orientation shown by the peak.

Abstract: By introducing a gas containing a reducing organic gas into the discharge space, the protective layer is exposed to the reducing organic gas. Then, the reducing organic gas is exhausted from the discharge space. Then, a discharge gas is enclosed to the discharge space. The protective layer includes a nano particle layer formed by nano crystal particles of metal oxides containing at least a first metal oxide and a second metal oxide. Moreover, the nano particle layer has at least one peak in an X-ray diffraction analysis. The peak is located between a first peak in the X-ray diffraction analysis of the first metal oxide and a second peak in the X-ray diffraction analysis of the second metal oxide. The first peak and the second peal have the same plane orientation as the plane orientation indicated by the peak.

Abstract: By introducing a gas containing a reducing organic gas into the discharge space, the protective layer is exposed to the reducing organic gas. Then, the reducing organic gas is exhausted from the discharge space. Then, a discharge gas is enclosed to the discharge space. The protective layer includes a base film made of magnesium oxide, and a plurality of metal oxide particles dispersed over the base film. The metal oxide particle includes at least a first metal oxide and a second metal oxide. Moreover, the metal oxide particle has at least one peak in an X-ray diffraction analysis. The peak is located between a first peak in the X-ray diffraction analysis of the first metal oxide and a second peak in the X-ray diffraction analysis of the second metal oxide. The first peak and the second peal have the same plane orientation as the plane orientation indicated by the peak.

Abstract: A plasma display has a protective layer (9) including a base layer (91) over which aggregate particles (92) each including an aggregate of a plurality of magnesium oxide crystal particles (92a) and metal oxide particles (93) are scattered. The metal oxide particles (93) contain at least two metal oxides selected from the group consisting of magnesium oxide, calcium oxide, strontium oxide, and barium oxide. X-ray diffraction analysis of the metal oxide particles (93) shows a diffraction peak of a specific crystal plane between a diffraction peak of the specific crystal plane of one of the two metal oxides and a diffraction peak of the specific crystal plane of another one of the two metal oxides.

Abstract: A plasma display has a protective layer (9) including a base layer (91) over which aggregate particles (92) each including an aggregate of a plurality of magnesium oxide crystal particles (92a) and metal oxide particles (93) are scattered. The metal oxide particles (93) contain at least two metal oxides selected from the group consisting of magnesium oxide, calcium oxide, strontium oxide, and barium oxide. X-ray diffraction analysis of the metal oxide particles (93) shows a diffraction peak of a specific crystal plane between a diffraction peak of the specific crystal plane of one of the two metal oxides and a diffraction peak of the specific crystal plane of another one of the two metal oxides.

Abstract: Provided is a PDP in which a weak discharge is always generated in a stable manner to lower the firing voltage, the generation of the reset luminous points is restricted to improve the image quality, and reduction of the luminous efficiency and reduction of the luminance are restricted to improve the luminance. A manufacturing method of the PDP is also provided. The PDP includes a front panel and a back panel arranged to face each other with a discharge space between the panels. A phosphor layer is provided in an area of the back panel that faces toward the discharge space. Part of the surface of the phosphor layer is covered with a phosphor-coating film as a high ? member. The phosphor-coating film is made of a material having a higher secondary electron emission coefficient than a material of the phosphor layer. The high ? member and the remaining are of the surface of the phosphor layer are exposed to the discharge space.